Does TAVR with a self-expanding prosthesis improve survival at 1 year compared to surgical aortic-valve replacement in patients with severe aortic stenosis at increased surgical risk?
In high-risk patients with severe aortic stenosis, TAVR with a self-expanding prosthesis significantly improves 1-year survival compared to surgical aortic-valve replacement.
In patients with severe aortic stenosis who are at increased surgical risk, TAVR with a self-expanding transcatheter aortic-valve bioprosthesis was associated with a significantly higher rate of survival at 1 year than surgical aortic-valve replacement. (Funded by Medtronic; U.S. CoreValve High Risk Study ClinicalTrials.gov number, NCT01240902.).
Adams et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: